Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 15/20 | 0.49 |
| ▸ | GGPS1 | O95749 | 4/20 | 0.41 |
| ▸ | BTN3A1 | O00481 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
| ▸ | MMP14 | P50281 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1157059 | 0.92 | GGPS1 (0.47) | FDPSGGPS1BTN3A1CA12CA2 | |
| SCHEMBL1028191 | 0.88 | FDPS (0.51) | FDPSGGPS1BTN3A1CA12CA2 | |
| SCHEMBL1029369 | 0.87 | FDPS (0.50) | FDPSGGPS1BTN3A1CA12CA2 | |
| SCHEMBL1027186 | 0.87 | FDPS (0.50) | FDPSGGPS1BTN3A1CA12CA2 | |
| Zinc Ion SCHEMBL1027185 | 0.82 | FDPS (0.43) | FDPSGGPS1BTN3A1CA12CA2 | |
| SCHEMBL1029368 | 0.82 | FDPS (0.43) | FDPSGGPS1BTN3A1CA12CA2 | |
| SCHEMBL2529194 | 0.81 | CYP11B1 (0.46) | FDPSGGPS1BTN3A1PDE3A | |
| SCHEMBL2532378 | 0.79 | FDPS (0.44) | FDPSGGPS1BTN3A1CA12CA2 | |
| SCHEMBL2532821 | 0.79 | CYP11B1 (0.50) | FDPSGGPS1BTN3A1PDE3A | |
| SCHEMBL1028197 | 0.78 | FDPS (0.58) | FDPSGGPS1BTN3A1CA12CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2225252-B1 | C2-C5-ALKYL-IMIDAZOLE-BISPHOSPHONATES | NOVARTIS AG (CH) | 2012-06-27 | — | — | EP | disclosed |
| EP-2225252-B1 | C2-C5-ALKYL-IMIDAZOLE-BISPHOSPHONATES | NOVARTIS AG (CH) | 2012-06-27 | — | — | EP | disclosed |
| US-20110224173-A1 | C2-C5-Alkyl-Imidazole-Bisphosphonates | NOVARTIS AG (CH) | 2011-09-15 | — | — | US | disclosed |
| US-20110224173-A1 | C2-C5-Alkyl-Imidazole-Bisphosphonates | NOVARTIS AG (CH) | 2011-09-15 | — | — | US | disclosed |
| US-20110224173-A1 | C2-C5-Alkyl-Imidazole-Bisphosphonates | NOVARTIS AG (CH) | 2011-09-15 | — | — | US | disclosed |
| US-7977323-B2 | C2-C5-alkyl-imidazole-bisphosphonates | NOVARTIS AG (CH) | 2011-07-12 | — | — | US | disclosed |
| US-7977323-B2 | C2-C5-alkyl-imidazole-bisphosphonates | NOVARTIS AG (CH) | 2011-07-12 | — | — | US | disclosed |
| US-7977323-B2 | C2-C5-alkyl-imidazole-bisphosphonates | NOVARTIS AG (CH) | 2011-07-12 | — | — | US | disclosed |
| US-20110034418-A1 | PHARMACEUTICAL COMPOSITION WITH BISPHOSPHONATE | NOVARTIS AG (CH) | 2011-02-10 | — | — | US | disclosed |
| US-20110034418-A1 | PHARMACEUTICAL COMPOSITION WITH BISPHOSPHONATE | NOVARTIS AG (CH) | 2011-02-10 | — | — | US | disclosed |
| US-20110034418-A1 | PHARMACEUTICAL COMPOSITION WITH BISPHOSPHONATE | NOVARTIS AG (CH) | 2011-02-10 | — | — | US | disclosed |
| EP-2273980-A2 | PHARMACEUTICAL COMPOSITION WITH BISPHOSPHONATE | Novartis AG (CH) | 2011-01-19 | — | — | EP | disclosed |
| WO-2009121935-A2 | PHARMACEUTICAL COMPOSITION WITH BISPHOSPHONATE | NOVARTIS AG (CH) | 2009-10-08 | — | — | WO | disclosed |
| WO-2009121935-A2 | PHARMACEUTICAL COMPOSITION WITH BISPHOSPHONATE | NOVARTIS AG (CH) | 2009-10-08 | — | — | WO | disclosed |
| US-20090143337-A1 | C2-C5-Alkyl-Imidazole-Bisphosphonates | NOVARTIS AG (CH) | 2009-06-04 | — | — | US | disclosed |
| US-20090143337-A1 | C2-C5-Alkyl-Imidazole-Bisphosphonates | NOVARTIS AG (CH) | 2009-06-04 | — | — | US | disclosed |
| US-20090143337-A1 | C2-C5-Alkyl-Imidazole-Bisphosphonates | NOVARTIS AG (CH) | 2009-06-04 | — | — | US | disclosed |
| WO-2009068567-A1 | C2-C5-ALKYL-IMIDAZOLE-BISPHOSPHONATES | NOVARTIS AG (CH) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224173-A1 | C2-C5-Alkyl-Imidazole-Bisphosphonates | INPP5B, PPIP5K2, INPPL1 | FDPS 231/4885GGPS1 5/4885BTN3A1 4194/4885 |
| US-20110034418-A1 | PHARMACEUTICAL COMPOSITION WITH BISPHOSPHONATE | SOST, SLC20A1, SLC34A1 | FDPS 390/4885GGPS1 159/4885BTN3A1 2781/4885 |
| US-20090143337-A1 | C2-C5-Alkyl-Imidazole-Bisphosphonates | PPIP5K2, INPP5B, INPPL1 | FDPS 235/4885GGPS1 5/4885BTN3A1 4199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.